Ren S, Cai P, Liu Y et al. Prevalence of Helicobacter pylori infection in China: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2022;37:464–470. https://doi.org/10.1111/jgh.15751.

Article  PubMed  Google Scholar 

Xia C, Dong X, Li H et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135:584–590. https://doi.org/10.1097/cm9.0000000000002108.

Article  PubMed  PubMed Central  Google Scholar 

Liu WZ, Xie Y, Lu H et al. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter. 2018;23:e12475. https://doi.org/10.1111/hel.12475.

Article  PubMed  Google Scholar 

Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66:6–30. https://doi.org/10.1136/gutjnl-2016-312288.

Article  CAS  PubMed  Google Scholar 

Liou JM, Malfertheiner P, Lee YC et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020;69:2093–2112. https://doi.org/10.1136/gutjnl-2020-322368.

Article  PubMed  Google Scholar 

Zhou L, Lu H, Song Z et al. 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. Chin Med J (Engl). 2022;135:2899–2910. https://doi.org/10.1097/CM9.0000000000002546.

Article  PubMed  PubMed Central  Google Scholar 

Kato MA-O, Ota H, Okuda MA-O, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2016 Revised Edition. Helicobacter. 2019.

Jung HK, Kang SJ, Lee YC et al. Evidence-Based Guidelines for the Treatment of Helicobacter pylori Infection in Korea 2020. Gut Liver. 2021;15:168–195. https://doi.org/10.5009/gnl20288.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ding YM, Li YY, Liu J et al. The cure rate of 10-day bismuth-containing quadruple therapy for Helicobacter pylori eradication is equivalent to 14-day: a systematic review and meta-analysis. Clin Exp Med. 2022. https://doi.org/10.1007/s10238-022-00953-7.

Article  PubMed  PubMed Central  Google Scholar 

Qiao C, Li Y, Liu J et al. Clarithromycin versus furazolidone for naïve Helicobacter pylori infected patients in a high clarithromycin resistance area. J Gastroenterol Hepatol. 2021;36:2383–2388. https://doi.org/10.1111/jgh.15468.

Article  CAS  PubMed  Google Scholar 

D’Agostino RB Sr, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Stat Med. 2003;22:169–186. https://doi.org/10.1002/sim.1425.

Article  PubMed  Google Scholar 

Liu DS, Wang YH, Zeng ZR et al. Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study. Clin Microbiol Infect. 2018;24:e5–e8. https://doi.org/10.1016/j.cmi.2017.11.010.

Article  CAS  Google Scholar 

Han Z, Li Y, Kong Q et al. Efficacy of bismuth for antibiotic-resistant Helicobacter pylori strains eradication: A systematic review and meta-analysis. Helicobacter. 2022;27:e12930. https://doi.org/10.1111/hel.12930.

Article  CAS  PubMed  Google Scholar 

Qian HS, Li WJ, Dang YN, et al. Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy. Am J Gastroenterol. 2023;118:627–34. https://doi.org/10.14309/ajg.0000000000002086.

Graham DY. It Is Time for a Paradigm Shift in Design, Execution, and Publishing of Comparative Helicobacter pylori Treatment Trials. Am J Gastroenterol. 2023;118:1154–6. https://doi.org/10.14309/ajg.0000000000002298.

Xu H, Yun J, Li R et al. Antibiotics Resistance Prevalence of Helicobacter pylori Strains in Northwest China. Infect Drug Resist. 2022;15:5519–5528. https://doi.org/10.2147/IDR.S383444.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shu X, Ye D, Hu C et al. Alarming antibiotics resistance of Helicobacter pylori from children in Southeast China over 6 years. Sci Rep. 2022;12:17754. https://doi.org/10.1038/s41598-022-21661-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kong Q, Li Y, Li R et al. Low compliance to post-screening recommendations in a family-based Helicobacter pylori screening and treatment program: A prospective cohort study. Helicobacter. 2022;27:e12912. https://doi.org/10.1111/hel.12912.

Article  CAS  PubMed  Google Scholar 

Tsuda M, Asaka M, Kato M, et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter. 2017;22. https://doi.org/10.1111/hel.12415.

Deguchi H, Uda A, Murakami K. Current Status of Helicobacter pylori Diagnosis and Eradication Therapy in Japan Using a Nationwide Database. Digestion. 2020;101:441–449. https://doi.org/10.1159/000500819.

Article  CAS  PubMed  Google Scholar 

Gao K, Wu J. National trend of gastric cancer mortality in China (2003–2015): a population-based study. Cancer Commun (Lond). 2019;39:24. https://doi.org/10.1186/s40880-019-0372-x.

Article  PubMed  PubMed Central  Google Scholar 

Han Y, Yan T, Ma H et al. Cost-Effectiveness Analysis of Helicobacter pylori Eradication Therapy for Prevention of Gastric Cancer: A Markov Model. Dig Dis Sci. 2020;65:1679–1688. https://doi.org/10.1007/s10620-019-05910-1.

Article  CAS  PubMed  Google Scholar 

Mason J, Axon AT, Forman D et al. The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. Aliment Pharmacol Ther. 2002;16:559–568. https://doi.org/10.1046/j.1365-2036.2002.01204.x.

Article  CAS  PubMed  Google Scholar 

Chiang TH, Chang WJ, Chen SL et al. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut. 2021;70:243–250. https://doi.org/10.1136/gutjnl-2020-322200.

Article  CAS  PubMed  Google Scholar 

Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 2008;5:321–331. https://doi.org/10.1038/ncpgasthep1138.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hori Y, Imanishi A, Matsukawa J et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010;335:231–238. https://doi.org/10.1124/jpet.110.170274.

Article  CAS  PubMed  Google Scholar 

Jenkins H, Sakurai Y, Nishimura A et al. Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015;41:636–648. https://doi.org/10.1111/apt.13121.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sakurai Y, Nishimura A, Kennedy G et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects. Clin Transl Gastroenterol. 2015;6:e94. https://doi.org/10.1038/ctg.2015.18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology. 2022;163:608–619. https://doi.org/10.1053/j.gastro.2022.05.055.

Article  CAS  PubMed  Google Scholar 

Rokkas T, Gisbert JP, Malfertheiner P et al. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Gastroenterology. 2021;161:495-507.e4. https://doi.org/10.1053/j.gastro.2021.04.012.

Article  CAS  PubMed  Google Scholar 

Graham DY, Lu H, Shiotani A. Vonoprazan-containing Helicobacter pylori triple therapies contribution to global antimicrobial resistance. J Gastroenterol Hepatol. 2021;36:1159–1163. https://doi.org/10.1111/jgh.15252.

Article  CAS  PubMed  Google Scholar 

Gisbert JP. Empirical or susceptibility-guided treatment for Helicobacter pylori infection? A comprehensive review. Therap Adv Gastroenterol. 2020;13:1756284820968736. https://doi.org/10.1177/1756284820968736.

Article  CAS  PubMed  Google Scholar 

Li P, Jin J, Chen Y, Ma J, Du Q, Han Y. Susceptibility-guided vs. empirical 10-day quadruple treatment for Helicobacter pylori-infected patients: A prospective clinical trial of first-line therapy. Front Microbiol. 2022;13:973975. https://doi.org/10.3389/fmicb.2022.973975.

Hsu PI, Tsai FW, Kao SS et al. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial. Am J Gastroenterol. 2017;11:1374–1381. https://doi.org/10.1038/ajg.2017.195.

Article  CAS  Google Scholar